ArticleClinical, cosmetic and investigational dermatology2026
Successful Treatment of Concurrent Bullous Pemphigoid and Psoriasis Vulgaris with Abrocitinib: A Case Report and Literature Review.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Upadacitinib for the treatment of refractory bullous pemphigoid: a case report and literature review.Frontiers in immunology · 2026Review
- Bullous Pemphigoid Possibly Induced by Deucravacitinib in a Patient with Psoriasis.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) and psoriasis are common immune-related dermatosis. The concurrence of these two diseases is rare. The coexistence of the two conditions imposes a difficult therapeutic challenge. We reported a case of concurrence of BP and psoriasis vulgaris which was successfully treated by abrocitinib. Based on our research, abrocitinib appears to be an effective and safe therapeutic option for patients with concurrent BP and psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.